2026 WCLC 丨岳东升教授：OSTAR 研究聚焦高危 Ⅰ 期 EGFR 突变 NSCLC，探索术后辅助靶向治疗新路径_腾讯新闻
引 言2026 年 9 月 12 日至 15...
王媛媛教授｜生存为尺，循证致远：国产三代EGFR‑TKI一线治疗新证据_腾讯新闻
前言近年来，随着表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKI）的更新迭代，E...
2026 CSCO｜袁瑛教授、张彦教授：双靶联合方案拓宽抗EGFR治疗获益边界，Crucial研究丰富KRAS G12C突变mCRC治疗选择_腾讯新闻
文章看点双靶联合±化疗展现强效缩瘤信号：氟泽雷塞联合西妥昔单抗β±FOLFIRI方...
Comparative profiling of osimertinib and fourth-generation EGFR inhibitors on EGFR-mutant proteins and cell lines
BackgroundOsimertinib is a third-generation, irreversible EGFR inhibitor that targets common activating EGFR mutations (ex19del and L858R) and the resistance Abstract Background: Osimertinib is a third-generation, irreversible EGFR inhibitor that targets common activating EGFR mutations (ex19del and L858R) and the resistance...
Induction and concurrent aumolertinib with radiotherapy for EGFR-mutated stage III NSCLC: results of phase III ADVANCE trial and real-world validation
The phase III ADVANCE study prospectively assessed a chemotherapy-free strategy combining aumolertinib with definitive radiotherapy (RT) in patients with unresectable stage III non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations (ChiCTR.org: ChiCTR2000040590). Participants were assigned in...
Association between initial eGFR dip and renal function trajectory in patients with chronic kidney disease initiating SGLT2 inhibitors: a retrospective cohort study
AbstractBackground Although sodium–glucose cotransporter 2 inhibitors (SGLT2is) induce an initial estimated glomerular filtration rate (eGFR) dip, its positive prognostic significance demonstrated in previous reports has not been fully translated into real-world practice. Misinterpretation of this dip often leads to “clinical...